Prevention of respiratory syncytial virus infections

Indications for the use of palivizumab and update on the use of RSV-IGIV

Neal A. Halsey, Jon S. Abramson, P. Joan Chesney, Margaret C. Fisher, Michael A. Gerber, S. Michael Marcy, Dennis L Murray, Gary D. Overturf, Charles G. Prober, Thomas N. Saari, Leonard B. Weiner, Richard J. Whitley, Robert F. Breiman, M. Carolyn Hardegree, Anthony Hirsch, Richard F. Jacobs, Noni E. MacDonald, Walter A. Orenstein, N. Regina Rabinovich, Ben Schwartz & 20 others Georges Peter, Carol J. Baker, Larry K. Pickering, H. Cody Meissner, James A. Lemons, Lillian R. Blackmon, William P. Kanto, Hugh M. MacDonald, Carol A. Miller, Lu Ann Papile, Warren Rosenfeld, Craig T. Shoemaker, Michael E. Speer, Michael F. Greene, Solomon Iyasu, Patricia Johnson, Douglas D. McMillan, Linda L. Wright, Jacob C. Langer, David K. Stevenson

Research output: Contribution to journalReview article

345 Citations (Scopus)

Abstract

The Food and Drug Administration recently approved the use of palivizumab (pale-vizhumab), an intramuscularly administered monoclonal antibody preparation. Recommendations for its use are based on a large, randomized study demonstrating a 55% reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients. Infants and children with chronic lung disease (CLD), formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without CLD experienced a reduced number of hospitalizations while receiving palivizumab compared with a placebo. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk children against serious complications from RSV infections. Palivizumab is preferred for most high-risk children because of ease of administration (intramuscular), lack of interference with measles-mumps-rubella vaccine and varicella vaccine, and lack of complications associated with intravenous administration of human immune globulin products. RSV-IGIV, however, provides additional protection against other respiratory vital illnesses and may be preferred for selected high- risk children including those receiving replacement intravenous immune globulin because of underlying immune deficiency or human immunodeficiency virus infection. For premature infants about to be discharged from hospitals during the RSV season, physicians could consider administering RSV-IGIV for the first month of prophylaxis. Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11% vs 10%, respectively); discontinuation of injections for adverse events related to palivizumab was rare.

Original languageEnglish (US)
Pages (from-to)1211-1216
Number of pages6
JournalPediatrics
Volume102
Issue number5
DOIs
StatePublished - Jan 1 1998

Fingerprint

Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Lung Diseases
Hospitalization
Chronic Disease
Placebos
Measles-Mumps-Rubella Vaccine
Chickenpox Vaccine
Pediatrics
Bronchopulmonary Dysplasia
Palivizumab
Intravenous Immunoglobulins
Virus Diseases
United States Food and Drug Administration
Risk Reduction Behavior
Premature Infants
Intravenous Administration
Immunoglobulins
Heart Diseases
Monoclonal Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Abramson, J. S., Chesney, P. J., Fisher, M. C., Gerber, M. A., Marcy, S. M., ... Stevenson, D. K. (1998). Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics, 102(5), 1211-1216. https://doi.org/10.1542/peds.102.5.1211

Prevention of respiratory syncytial virus infections : Indications for the use of palivizumab and update on the use of RSV-IGIV. / Halsey, Neal A.; Abramson, Jon S.; Chesney, P. Joan; Fisher, Margaret C.; Gerber, Michael A.; Marcy, S. Michael; Murray, Dennis L; Overturf, Gary D.; Prober, Charles G.; Saari, Thomas N.; Weiner, Leonard B.; Whitley, Richard J.; Breiman, Robert F.; Carolyn Hardegree, M.; Hirsch, Anthony; Jacobs, Richard F.; MacDonald, Noni E.; Orenstein, Walter A.; Rabinovich, N. Regina; Schwartz, Ben; Peter, Georges; Baker, Carol J.; Pickering, Larry K.; Meissner, H. Cody; Lemons, James A.; Blackmon, Lillian R.; Kanto, William P.; MacDonald, Hugh M.; Miller, Carol A.; Papile, Lu Ann; Rosenfeld, Warren; Shoemaker, Craig T.; Speer, Michael E.; Greene, Michael F.; Iyasu, Solomon; Johnson, Patricia; McMillan, Douglas D.; Wright, Linda L.; Langer, Jacob C.; Stevenson, David K.

In: Pediatrics, Vol. 102, No. 5, 01.01.1998, p. 1211-1216.

Research output: Contribution to journalReview article

Halsey, NA, Abramson, JS, Chesney, PJ, Fisher, MC, Gerber, MA, Marcy, SM, Murray, DL, Overturf, GD, Prober, CG, Saari, TN, Weiner, LB, Whitley, RJ, Breiman, RF, Carolyn Hardegree, M, Hirsch, A, Jacobs, RF, MacDonald, NE, Orenstein, WA, Rabinovich, NR, Schwartz, B, Peter, G, Baker, CJ, Pickering, LK, Meissner, HC, Lemons, JA, Blackmon, LR, Kanto, WP, MacDonald, HM, Miller, CA, Papile, LA, Rosenfeld, W, Shoemaker, CT, Speer, ME, Greene, MF, Iyasu, S, Johnson, P, McMillan, DD, Wright, LL, Langer, JC & Stevenson, DK 1998, 'Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV', Pediatrics, vol. 102, no. 5, pp. 1211-1216. https://doi.org/10.1542/peds.102.5.1211
Halsey, Neal A. ; Abramson, Jon S. ; Chesney, P. Joan ; Fisher, Margaret C. ; Gerber, Michael A. ; Marcy, S. Michael ; Murray, Dennis L ; Overturf, Gary D. ; Prober, Charles G. ; Saari, Thomas N. ; Weiner, Leonard B. ; Whitley, Richard J. ; Breiman, Robert F. ; Carolyn Hardegree, M. ; Hirsch, Anthony ; Jacobs, Richard F. ; MacDonald, Noni E. ; Orenstein, Walter A. ; Rabinovich, N. Regina ; Schwartz, Ben ; Peter, Georges ; Baker, Carol J. ; Pickering, Larry K. ; Meissner, H. Cody ; Lemons, James A. ; Blackmon, Lillian R. ; Kanto, William P. ; MacDonald, Hugh M. ; Miller, Carol A. ; Papile, Lu Ann ; Rosenfeld, Warren ; Shoemaker, Craig T. ; Speer, Michael E. ; Greene, Michael F. ; Iyasu, Solomon ; Johnson, Patricia ; McMillan, Douglas D. ; Wright, Linda L. ; Langer, Jacob C. ; Stevenson, David K. / Prevention of respiratory syncytial virus infections : Indications for the use of palivizumab and update on the use of RSV-IGIV. In: Pediatrics. 1998 ; Vol. 102, No. 5. pp. 1211-1216.
@article{607ce2baa99041ec8266256811153e29,
title = "Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV",
abstract = "The Food and Drug Administration recently approved the use of palivizumab (pale-vizhumab), an intramuscularly administered monoclonal antibody preparation. Recommendations for its use are based on a large, randomized study demonstrating a 55{\%} reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients. Infants and children with chronic lung disease (CLD), formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without CLD experienced a reduced number of hospitalizations while receiving palivizumab compared with a placebo. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk children against serious complications from RSV infections. Palivizumab is preferred for most high-risk children because of ease of administration (intramuscular), lack of interference with measles-mumps-rubella vaccine and varicella vaccine, and lack of complications associated with intravenous administration of human immune globulin products. RSV-IGIV, however, provides additional protection against other respiratory vital illnesses and may be preferred for selected high- risk children including those receiving replacement intravenous immune globulin because of underlying immune deficiency or human immunodeficiency virus infection. For premature infants about to be discharged from hospitals during the RSV season, physicians could consider administering RSV-IGIV for the first month of prophylaxis. Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11{\%} vs 10{\%}, respectively); discontinuation of injections for adverse events related to palivizumab was rare.",
author = "Halsey, {Neal A.} and Abramson, {Jon S.} and Chesney, {P. Joan} and Fisher, {Margaret C.} and Gerber, {Michael A.} and Marcy, {S. Michael} and Murray, {Dennis L} and Overturf, {Gary D.} and Prober, {Charles G.} and Saari, {Thomas N.} and Weiner, {Leonard B.} and Whitley, {Richard J.} and Breiman, {Robert F.} and {Carolyn Hardegree}, M. and Anthony Hirsch and Jacobs, {Richard F.} and MacDonald, {Noni E.} and Orenstein, {Walter A.} and Rabinovich, {N. Regina} and Ben Schwartz and Georges Peter and Baker, {Carol J.} and Pickering, {Larry K.} and Meissner, {H. Cody} and Lemons, {James A.} and Blackmon, {Lillian R.} and Kanto, {William P.} and MacDonald, {Hugh M.} and Miller, {Carol A.} and Papile, {Lu Ann} and Warren Rosenfeld and Shoemaker, {Craig T.} and Speer, {Michael E.} and Greene, {Michael F.} and Solomon Iyasu and Patricia Johnson and McMillan, {Douglas D.} and Wright, {Linda L.} and Langer, {Jacob C.} and Stevenson, {David K.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1542/peds.102.5.1211",
language = "English (US)",
volume = "102",
pages = "1211--1216",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Prevention of respiratory syncytial virus infections

T2 - Indications for the use of palivizumab and update on the use of RSV-IGIV

AU - Halsey, Neal A.

AU - Abramson, Jon S.

AU - Chesney, P. Joan

AU - Fisher, Margaret C.

AU - Gerber, Michael A.

AU - Marcy, S. Michael

AU - Murray, Dennis L

AU - Overturf, Gary D.

AU - Prober, Charles G.

AU - Saari, Thomas N.

AU - Weiner, Leonard B.

AU - Whitley, Richard J.

AU - Breiman, Robert F.

AU - Carolyn Hardegree, M.

AU - Hirsch, Anthony

AU - Jacobs, Richard F.

AU - MacDonald, Noni E.

AU - Orenstein, Walter A.

AU - Rabinovich, N. Regina

AU - Schwartz, Ben

AU - Peter, Georges

AU - Baker, Carol J.

AU - Pickering, Larry K.

AU - Meissner, H. Cody

AU - Lemons, James A.

AU - Blackmon, Lillian R.

AU - Kanto, William P.

AU - MacDonald, Hugh M.

AU - Miller, Carol A.

AU - Papile, Lu Ann

AU - Rosenfeld, Warren

AU - Shoemaker, Craig T.

AU - Speer, Michael E.

AU - Greene, Michael F.

AU - Iyasu, Solomon

AU - Johnson, Patricia

AU - McMillan, Douglas D.

AU - Wright, Linda L.

AU - Langer, Jacob C.

AU - Stevenson, David K.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The Food and Drug Administration recently approved the use of palivizumab (pale-vizhumab), an intramuscularly administered monoclonal antibody preparation. Recommendations for its use are based on a large, randomized study demonstrating a 55% reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients. Infants and children with chronic lung disease (CLD), formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without CLD experienced a reduced number of hospitalizations while receiving palivizumab compared with a placebo. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk children against serious complications from RSV infections. Palivizumab is preferred for most high-risk children because of ease of administration (intramuscular), lack of interference with measles-mumps-rubella vaccine and varicella vaccine, and lack of complications associated with intravenous administration of human immune globulin products. RSV-IGIV, however, provides additional protection against other respiratory vital illnesses and may be preferred for selected high- risk children including those receiving replacement intravenous immune globulin because of underlying immune deficiency or human immunodeficiency virus infection. For premature infants about to be discharged from hospitals during the RSV season, physicians could consider administering RSV-IGIV for the first month of prophylaxis. Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11% vs 10%, respectively); discontinuation of injections for adverse events related to palivizumab was rare.

AB - The Food and Drug Administration recently approved the use of palivizumab (pale-vizhumab), an intramuscularly administered monoclonal antibody preparation. Recommendations for its use are based on a large, randomized study demonstrating a 55% reduction in the risk of hospitalization attributable to respiratory syncytial virus (RSV) infections in high-risk pediatric patients. Infants and children with chronic lung disease (CLD), formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without CLD experienced a reduced number of hospitalizations while receiving palivizumab compared with a placebo. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk children against serious complications from RSV infections. Palivizumab is preferred for most high-risk children because of ease of administration (intramuscular), lack of interference with measles-mumps-rubella vaccine and varicella vaccine, and lack of complications associated with intravenous administration of human immune globulin products. RSV-IGIV, however, provides additional protection against other respiratory vital illnesses and may be preferred for selected high- risk children including those receiving replacement intravenous immune globulin because of underlying immune deficiency or human immunodeficiency virus infection. For premature infants about to be discharged from hospitals during the RSV season, physicians could consider administering RSV-IGIV for the first month of prophylaxis. Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11% vs 10%, respectively); discontinuation of injections for adverse events related to palivizumab was rare.

UR - http://www.scopus.com/inward/record.url?scp=0031729747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031729747&partnerID=8YFLogxK

U2 - 10.1542/peds.102.5.1211

DO - 10.1542/peds.102.5.1211

M3 - Review article

VL - 102

SP - 1211

EP - 1216

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -